This webinar aims to provide insights into immunofluorescence-based biomarker analysis with key considerations for developing a companion diagnostic (CDx). These include avoiding common pitfalls associated with multiplex immunofluorescence and multispectral imaging, and successfully harnessing its full potential in the clinical setting.
Recently, there have been many advancements in examining biomarker expression and heterogeneity within the tumor microenvironment using high-throughput technologies. However, current clinical tests for biomarkers often fall short in providing sufficient information to effectively predict treatment response.
Multiplex fluorescence immunohistochemistry and image data analysis have helped uncover meaningful spatial relationships between specific biomarkers, offering valuable insights into patient responses to immune checkpoint inhibitors, antibody-drug conjugates (ADCs) and DNA damage response (DDR) targeted therapies. These techniques have become indispensable for gathering critical data from clinical programs.
Multiplex fluorescence immunohistochemistry and image data analysis have helped uncover meaningful spatial relationships between specific biomarkers, offering valuable insights into patient responses to immune checkpoint inhibitors, antibody-drug conjugates (ADCs) and DNA damage response (DDR) targeted therapies. These techniques have become indispensable for gathering critical data from clinical programs.
As multiplex immunofluorescence techniques mature as an analytical platform, it is important to understand the technology’s fundamentals and its application in assessing response for both mono- and combination therapies.
Related Posts
Accelerate Building Custom Spatial Proteomic Panels for New Biological Insights
Ultrasensitive Neuroimmune Biomarker Measurement for Translational Research and Therapeutic Development
Underdiagnosis of Alzheimer’s disease pathology in patients with cardiovascular disease
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…